Cancer
Malignant Central Nervous System Neoplasm
CI-CAN-00001115Explore in graph →
Top-level822 active trials5 approved drugs103 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001115Explore in graph →
Clinical trials
2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (418)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02617589 | An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)(CheckMate 498) | completed | Phase 3 | 560 | Bristol-Myers SquibbINDUSTRY | 19 | Mar 28, 2023 | clinicaltrials |
| NCT04630379 | Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers | completed | N/A | 16 | Mayo ClinicOTHER | 1 |
| Mar 20, 2023 |
| clinicaltrials |
| NCT00639639 | Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme(ATTAC) | completed | Phase 1 | 42 | Gary Archer Ph.D.OTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT05171127 | Differentiation Between Healthy Cerebral Tissue and Tumor Tissue Using a Tissue Sensing Instrument | completed | — | 31 | Karolinska University HospitalOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT04205357 | Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma(SAS-GKRS) | completed | Phase 1 | 24 | Haukeland University HospitalOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT01269424 | BG & TMZ Therapy of Glioblastoma Multiforme | completed | Phase 1 | 10 | Stanton Gerson MDOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT00565903 | Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome(PPB) | completed | — | 1,247 | Ashley HillOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03867123 | A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients | completed | Phase 1 | 18 | Laminar PharmaceuticalsINDUSTRY | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04334863 | WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors | completed | Phase 1 | 10 | Emory UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02022384 | Immunophenotyping From Blood of Patients With Malignant Gliomas | completed | — | 50 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT00100802 | Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 1 | Feb 15, 2023 | clinicaltrials |
| NCT02997423 | Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM) | completed | — | 153 | University of IowaOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT03273712 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | completed | Phase 2 | 39 | University of IowaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02296580 | A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) | completed | N/A | 37 | Nativis, Inc.INDUSTRY | 2 | Feb 2, 2023 | clinicaltrials |
| NCT03276286 | Nativis Voyager for Newly Diagnosed GBM(NAT109) | completed | N/A | 37 | Nativis, Inc.INDUSTRY | 1 | Feb 2, 2023 | clinicaltrials |
| NCT03072134 | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | completed | Phase 1 | 12 | Northwestern UniversityOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT02829931 | Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas | completed | Phase 1 | 33 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04657315 | Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients(MSC11FCD-GBM) | completed | Phase 1 / Phase 2 | 10 | CHA UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03355794 | A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | completed | Phase 1 | 19 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT02311920 | Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | completed | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT02017964 | Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma | completed | Phase 2 | 26 | Children's Oncology GroupNETWORK | 4 | Jan 9, 2023 | clinicaltrials |
| NCT05671016 | Brain Imaging to Predict Toxicity in Elderly Patients After Radiotherapy(BRITER) | completed | — | 125 | Brighton and Sussex University Hospitals NHS TrustOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT01730950 | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 182 | Radiation Therapy Oncology GroupNETWORK | 1 | Dec 29, 2022 | clinicaltrials |
| NCT01974804 | Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis | completed | — | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT02849171 | Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas | completed | N/A | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT03520504 | Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases | completed | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT04444427 | Evaluation of GLR2007 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 19 | Gan and Lee Pharmaceuticals, USAINDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT04934579 | Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma | completed | Phase 2 | 17 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT01301430 | Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.(ParvOryx01) | completed | Phase 1 / Phase 2 | 18 | Oryx GmbH & Co. KGINDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT01647971 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 39 | TG Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT04132843 | Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions | completed | N/A | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 21, 2022 | clinicaltrials |
| NCT01865162 | Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study(KGDinGBM) | completed | Phase 1 | 6 | Mid-Atlantic Epilepsy and Sleep Center, LLCOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT03291977 | Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)(FLEGME) | completed | Phase 3 | 51 | Rennes University HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT04860934 | Dual Task Training On Children With Ataxia After Medulloblastoma Resection | completed | N/A | 30 | Children's Cancer Hospital Egypt 57357OTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02274987 | Molecular Profiling for Individualized Treatment Plan for DIPG | completed | N/A | 38 | University of California, San FranciscoOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02858895 | Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 47 | Medicenna Therapeutics, Inc.INDUSTRY | 1 | Oct 24, 2022 | clinicaltrials |
| NCT04114786 | 3D Printed Mask for GBM and Brain Mets | completed | N/A | 40 | University Health Network, TorontoOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT01469247 | Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT) | completed | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02336165 | Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma | completed | Phase 2 | 159 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 12, 2022 | clinicaltrials |
| NCT00687765 | Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 / Phase 2 | 126 | SanofiINDUSTRY | 1 | Sep 14, 2022 | clinicaltrials |
| NCT02926222 | Regorafenib in Relapsed Glioblastoma(REGOMA) | completed | Phase 2 | 119 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 9, 2022 | clinicaltrials |
| NCT03744026 | Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9(SC9-GBM-01) | completed | Phase 1 / Phase 2 | 38 | CarTheraINDUSTRY | 2 | Sep 7, 2022 | clinicaltrials |
| NCT03020017 | NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery | completed | Early Phase 1 | 8 | Northwestern UniversityOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT02302235 | Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study(GBMXRT) | completed | Phase 2 | 42 | Mid-Atlantic Epilepsy and Sleep Center, LLCOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT04596930 | MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma(EMITT) | completed | N/A | 15 | Radboud University Medical CenterOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT03342586 | Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity | completed | — | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT00731731 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01458730 | Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | completed | Phase 2 | 66 | University of AarhusOTHER | 1 | Aug 4, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 28, 2023source: clinicaltrials